Sanofi-Aventis' 2010 Guidance Remains Unchanged; Q1 Sales Up 3.9 %
This article was originally published in The Pink Sheet Daily
Executive Summary
The onset of Lovenox generics could be a near-term reality in the U.S., though timing remains uncertain.
You may also be interested in...
ABC Sees Double Opportunity For Wholesalers In Biosimilars
AmerisourceBergen is anticipating that the establishment of an FDA approval pathway for biosimilars under health care reform will have a real upside for drug wholesalers
ABC Sees Double Opportunity For Wholesalers In Biosimilars
AmerisourceBergen is anticipating that the establishment of an FDA approval pathway for biosimilars under health care reform will have a real upside for drug wholesalers
Sanofi-Aventis Enters Diabetes Pact With AgaMatrix For Blood Glucose Monitors
AgaMatrix will develop a portfolio of blood glucose monitors exclusively for Sanofi-Aventis, which can now market an array of diabetes products.